<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cue Biopharma — News on 6ix</title>
<link>https://6ix.com/company/cue-biopharma</link>
<description>Latest news and press releases for Cue Biopharma on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 12:37:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cue-biopharma" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355abb78dffbe2df0eb9a3.webp</url>
<title>Cue Biopharma</title>
<link>https://6ix.com/company/cue-biopharma</link>
</image>
<item>
<title>Cue Biopharma Announces 1-for-30 Reverse Stock Split</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-1-for-30-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-1-for-30-reverse-stock-split</guid>
<pubDate>Wed, 22 Apr 2026 12:37:00 GMT</pubDate>
<description>BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that it will implement a 1-for-30 reverse stock split of the issued shares of the company’s common stock, effective at 5:00 p.m. Eastern Time on April 23, 2026. The reverse stock split was appro</description>
</item>
<item>
<title>Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of</description>
</item>
<item>
<title>Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-to-receive-dollar75-million-preclinical-milestone-payment-from-boehringer-ingelheim-collaboration-and-license-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-to-receive-dollar75-million-preclinical-milestone-payment-from-boehringer-ingelheim-collaboration-and-license-agreement</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Preclinical milestone for selection and approval of first compound for lead optimization has been achievedFurther development validates the potential intended</description>
</item>
<item>
<title>Cue Biopharma Announces CEO Transition</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-ceo-transition</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-ceo-transition</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Lucinda Warren Appointed Interim President and Chief Executive Officer – Usman Azam Steps Down BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.</description>
</item>
<item>
<title>Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-to-host-virtual-randd-day-event-on-april-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-to-host-virtual-randd-day-event-on-april-7-2026</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and KOLs will discuss</description>
</item>
<item>
<title>Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights</guid>
<pubDate>Mon, 16 Mar 2026 20:05:00 GMT</pubDate>
<description>Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseasesAppointed industry veteran Lucinda Warren as Chief Financial and Business OfficerRaised net proceeds of $10.2M through an underwritten public offeringAnnounced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Entitled to receive upfront</description>
</item>
<item>
<title>Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-to-present-new-in-vitro-data-for-cue-401-at-the-20th-world-immune-regulation-meeting-wirm-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-to-present-new-in-vitro-data-for-cue-401-at-the-20th-world-immune-regulation-meeting-wirm-2026</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of</description>
</item>
<item>
<title>Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-preclinical-safety-130000749</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-preclinical-safety-130000749</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced pre</description>
</item>
<item>
<title>Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-appoints-industry-veteran-130000545</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-appoints-industry-veteran-130000545</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma’s chief business officer (CBO) since September 2024, has been appointed chief financial and business officer (CFBO) effective February 9, 2026</description>
</item>
<item>
<title>Cue Biopharma Announces Pricing of $10 Million Public Offering</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-pricing-10-130000982</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-pricing-10-130000982</guid>
<pubDate>Fri, 19 Dec 2025 13:00:00 GMT</pubDate>
<description>BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying common stock warrants to purchas</description>
</item>
<item>
<title>Cue Biopharma Announces Proposed Public Offering</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-proposed-public-210200429</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-proposed-public-210200429</guid>
<pubDate>Thu, 18 Dec 2025 21:02:00 GMT</pubDate>
<description>BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. I</description>
</item>
<item>
<title>Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-reports-third-quarter-210500646</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-reports-third-quarter-210500646</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M Announced strategic transition in leadership to further enable next stage of growth with disruptive autoimmune therapeutic candidates, most notably CUE-401, the Company’s lead autoimmune asset BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceut</description>
</item>
<item>
<title>Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-immunoscape-announce-strategic-130000615</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-immunoscape-announce-strategic-130000615</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs®Novel therapeutic approach is designed to enable in vivo expansion and activation of infused T cell receptor engineered T cells (TCR-Ts) to provide durability, tolerability and enhanced clinical benefit while reducing manufacturing complexityCompelling data generated in preclinical models of multiple solid tumors, includi</description>
</item>
<item>
<title>Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-strategic-transition-130000805</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-strategic-transition-130000805</guid>
<pubDate>Mon, 29 Sep 2025 13:00:00 GMT</pubDate>
<description>Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic Advisor to provide ongoing support to the Company Cue Biopharma prioritizes autoimmune disease for next stage of growth with focus on advancing first-in-class tolerogenic biologic CUE-401 into the clinic BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage</description>
</item>
<item>
<title>Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-participate-fireside-chat-120000391</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-participate-fireside-chat-120000391</guid>
<pubDate>Thu, 21 Aug 2025 12:00:00 GMT</pubDate>
<description>BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held in New York, September 3-5, 2025. During the fireside chat, Cue Biopharma will discuss program updates f</description>
</item>
<item>
<title>Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-initiation-investigator-120000045</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-announces-initiation-investigator-120000045</guid>
<pubDate>Wed, 13 Aug 2025 12:00:00 GMT</pubDate>
<description>First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, announced today the initiation of an investigator sponsored trial (IST) in rGBM at the DFCI with the</description>
</item>
<item>
<title>Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-reports-second-quarter-200500618</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-reports-second-quarter-200500618</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>Received FDA feedback on Pre-IND Briefing Document reinforcing Company’s intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases. Upfront payment of $12 million and ~$345 million in potential milestone payme</description>
</item>
<item>
<title>Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-reports-complete-response-120000520</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-reports-complete-response-120000520</guid>
<pubDate>Wed, 16 Jul 2025 12:00:00 GMT</pubDate>
<description>Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19)12-month overall survival of 88% and median overall survival (mOS) of 32 months BOSTON, July 16, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modul</description>
</item>
<item>
<title>Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-provides-most-advanced-200500444</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-provides-most-advanced-200500444</guid>
<pubDate>Tue, 01 Jul 2025 20:05:00 GMT</pubDate>
<description>ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 months BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided an update on its most advanced clinical stage asset, CUE-101, representative of the CUE-10</description>
</item>
<item>
<title>Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease</title>
<link>https://6ix.com/company/cue-biopharma/news/cue-biopharma-receives-fda-feedback-204800076</link>
<guid isPermaLink="true">https://6ix.com/company/cue-biopharma/news/cue-biopharma-receives-fda-feedback-204800076</guid>
<pubDate>Tue, 24 Jun 2025 20:48:00 GMT</pubDate>
<description>CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced it has received Pre-Investigational New Drug (P</description>
</item>
</channel>
</rss>